Trial · NCT06642181
Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder
NCT06642181, Phase 1, Recruiting, Rutgers, The State University of New Jersey
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder. Trials, record NCT06642181. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06642181
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder
- NCT number
- NCT06642181
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 224 participants, estimated
- Lead sponsor
- Rutgers, The State University of New Jersey
- Conditions
- Mindfulness, Guanfacine, Opioid Use Disorder
- Interventions
- Guanfacine pharmacotherapy, Mindfulness Oriented Recovery Enhancement (MORE)
- First posted
- 2024-10-15
- Last updated
- 2025-08-08
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Craving | At pre- and post-intervention (6 weeks intervention) | Self report of opioid craving will be collected. Will be measured using a likert scale 0 (not at all) to 10 (extreme). |
| Primary | Anxiety | At pre- and post-intervention (6 weeks intervention) | Self report of anxiety will be collected. Will be measured using a likert scale 0 (not at all) to 10 (extreme). . |
| Primary | Stress | At pre- and post-intervention (6 weeks intervention) | Self report of stress will be collected. Will be measured using a likert scale 0 (not at all) to 10 (extreme). |
| Primary | Mood | At pre- and post-intervention (6 weeks intervention) | Self report of mood will be collected. Positive and negative mood will be collected on a 4 point likert scale 0 (not at all) and 4 (extreme) |
| Primary | Emotional Dysregulation | At pre- and post-intervention (6 weeks intervention) | Self report of emotional dysregulation data will be collected. Will be measured using a 10 point likert scale (0=not at all) and 10 (extreme) |
| Primary | Heart Rate | At pre- and post-intervention (6 weeks intervention) | Heart rate data will be collected using an EKG monitor during the entire lab procedure while the participants will hear stress, opioid, and neutral related scripts. |
| Primary | Brain Activation | At pre- and post-intervention (6 weeks intervention) | Brain activation data will be collected using Blood Oxygen Level Dependent (BOLD) signal during functional magnetic resonance imaging (fMRI) while participants hear stress, opioid and neutral scripts. |
| Primary | Brain Connectivity | At pre- and post-intervention (6 weeks intervention) | Brain connectivity data will be collected using Blood Oxygen Level Dependent (BOLD) signal during functional magnetic resonance imaging (fMRI) while participants hear stress, opioid and neutral scripts. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R61DA059906 | Combined guanfacine and mindfulness meditation as an adjunct to buprenorphine maintenance in OUD | RAY, SUCHISMITA; FOX, HELEN CECILIA | RUTGERS BIOMEDICAL AND HEALTH SCIENCES | NATIONAL INSTITUTE ON DRUG ABUSE | 2024 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06642181
GET https://conductscience.org/api/trials/v1/NCT06642181/registered